Welcome to our dedicated page for IPSEN SA S/ADR news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on IPSEN SA S/ADR stock.
IPSEN SA S/ADR (IPSEY) is a global biopharmaceutical company focused on transformative medicines in oncology, rare disease, and neuroscience. Recently, they have achieved Health Canada approval for Bylvay™ (odevixibat) for treating pruritus in patients with Progressive Familial Intrahepatic Cholestasis (PFIC). Bylvay is a non-systemic ileal bile acid transport inhibitor offering new hope for patients with PFIC. The company is involved in multiregional partnerships to expand access to innovative therapies globally.
Ipsen has reported its total share capital and voting rights as of 31 July 2022. The total number of shares is 83,814,526. The gross total of voting rights stands at 132,118,807, while the net total is 130,970,618. This report follows regulatory requirements under French law, specifically Article L.233-8 II and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers.
On February 8, 2022, Ipsen reported a transaction involving the purchase of 8,000 shares at a daily weighted average price of €95.4471 on the XPAR platform. The issuer identification code is 549300M6SGDPB4Z94P11, with the financial instrument's identification code being FR0010259150. This acquisition reflects Ipsen's active engagement in market activities, underscoring the company's commitment to managing its share capital effectively.
Ipsen S.A. has extended the expiration date for its tender offer to acquire Epizyme, Inc. shares to August 11, 2022. The offer values Epizyme shares at $1.45 each, plus a contingent value right potentially worth up to $1.00. This extension allows additional time for compliance with the Hart-Scott-Rodino Antitrust Improvements Act. As of August 4, 2022, approximately 42.3 million shares—around 25% of Epizyme's outstanding shares—have been tendered. Stockholders are encouraged to accept the offer, and previously tendered shares do not need to be re-submitted.
Ipsen announced that its Phase III RESILIENT trial for Onivyde (irinotecan liposomal injection) in small cell lung cancer did not meet the primary endpoint of overall survival compared to topotecan. Although the trial did show a doubling of the objective response rate in favor of Onivyde, it raises concerns for investors regarding efficacy. The safety profile remained consistent with previous studies, causing no new safety issues. Detailed results will be shared at a medical conference, and data will be communicated to regulatory agencies.
On July 26, 2022, Ipsen reported aggregate trading details, highlighting a total volume of 9,218 shares across two transaction days. The daily weighted average price of shares was 91.0254 on July 25, and 89.2192 on July 26. The data indicates notable trading activity on the XPAR platform, revealing key metrics that investors should analyze. The information is crucial for assessing market movements and potential investment decisions for IPSEY.
Ipsen has partnered with Marengo Therapeutics to develop two preclinical oncology candidates using Marengo's TCR Vβ-targeted T cell activation approach. Ipsen will pay $45 million upfront and may pay up to $1.592 billion in milestone payments, plus royalties. Marengo will lead preclinical development, with Ipsen handling clinical development and commercialization. This collaboration aims to enhance Ipsen's oncology pipeline, with both companies bringing substantial expertise to the partnership.
Ipsen (Euronext: IPN; ADR: IPSEY) reported strong H1 2022 financial results with a total sales increase of 15.2% to €1.43 billion, driven by robust growth in oncology and neuroscience segments. Core consolidated net profit rose by 19.9% to €420 million, while IFRS net profit jumped 30% to €394 million. The core operating margin improved to 39.6%. Ipsen announced an agreement to acquire Epizyme to enhance its oncology portfolio and completed the divestiture of its Consumer HealthCare business. Full-year guidance was upgraded to reflect anticipated sales growth of over 7% at constant currency.
IPSEN reported an aggregated presentation of financial transactions for its shares on the XPAR platform for the week of July 18-22, 2022. Total transactions included 8,911 shares with a daily weighted average price of €92.4400. Key transaction dates were July 18, 20, 21, and 22, with notable volumes including 4,500 shares on July 18 and 2,300 shares on July 22. This release provides insight into the trading activity of IPSEN, which is essential for investors tracking market performance.
The press release from Ipsen details a recent stock transaction involving 2,027 shares at a weighted average price of 91.9164 on July 15, 2022. The issuer identification code provided is 549300M6SGDPB4Z94P11, with the financial instrument code being FR0010259150. The transaction occurred on the XPAR platform.
Ipsen has reported essential updates regarding its share capital as of 30 June 2022. The total number of shares amount to 83,814,526, with a gross total of 132,114,538 voting rights and a net total of 130,987,438 voting rights. This information follows the regulations outlined by the French Commercial Code and the Autorité des Marchés Financiers. The gross total includes shares with double voting rights and treasury shares, while the net total excludes shares without voting rights.
FAQ
What is the current stock price of IPSEN SA S/ADR (IPSEY)?
What is the market cap of IPSEN SA S/ADR (IPSEY)?
What is IPSEN SA S/ADR focused on?
What recent achievement has IPSEN SA S/ADR made?
What is Bylvay™ (odevixibat)?
What are IPSEN SA S/ADR's partnerships focused on?
